Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, July 2000, p. 1865-1868, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
In Vivo Increase in Resistance to Ciprofloxacin in
Escherichia coli Associated with Deletion of the C-Terminal
Part of MarR
Hans-Jörg
Linde,1
Frank
Notka,1
Michaela
Metz,1
Bernd
Kochanowski,1
Peter
Heisig,2 and
Norbert
Lehn1,*
Institute for Medical Microbiology and
Hygiene, University of Regensburg, Regensburg,1
and Pharmazeutische Mikrobiologie, Universität Bonn,
Bonn,2 Germany
Received 24 November 1999/Returned for modification 28 January
2000/Accepted 21 April 2000
 |
ABSTRACT |
We recovered two isolates (EP1 and EP2) of Escherichia
coli from the same patient that had identical pulsed-field gel
electrophoresis patterns but required different MICs of ciprofloxacin
(CIP): 16 and 256 mg/liter for EP1 and EP2, respectively. Both isolates had mutations in the quinolone resistance-determining regions of GyrA
(Ser83Leu and Asp87Tyr) and ParC (Ser80Ile), but not in those regions
of GyrB or ParE. Isolate EP2 was also more resistant to
chloramphenicol, tetracyclines, cefuroxime, and organic solvents. A
deletion of adenine (A) 1821 was found in marR of isolate
EP2, which resulted in an 18-amino-acid C-terminal deletion in the MarR
protein. The causative relationship between
A1821 and the Mar
phenotype was demonstrated both by the replacement of the wild-type
marR by marR
A1821 in isolate EP1 and by
complementation with the wild-type marR in
trans in isolate EP2. In isolate EP2 complemented with
wild-type marR, susceptibility to chloramphenicol was
restored completely, whereas susceptibility to CIP was restored only
incompletely. Northern blotting demonstrated increased expression of
marA and acrAB but not of soxS in
isolate EP2 compared to EP1. In conclusion, the deletion of A1821 in
marR in the clinical isolate EP2 caused an increase in the
MICs of CIP and unrelated antibiotics. Presumably, the C-terminal part
of MarR is necessary for proper repressor function.
 |
INTRODUCTION |
Resistance mechanisms of
Escherichia coli against fluoroquinolones (FQ) have been
well studied, and three mechanisms have been identified. Point
mutations in the quinolone resistance-determining regions (QRDRs) of
topoisomerases II (gyrAB) and IV (parCE) lead to
a stepwise acquisition of resistance (7, 9, 12). Active efflux of FQ by multidrug resistance pumps like AcrAB, and reduced uptake due to OmpF, both regulated by the transcription factor MarA,
are also implicated in resistance (5, 18). These mechanisms, often in combination, have been found in strains from both in vitro and
clinical investigations. However, few data are available about the
development of resistance in patients, that is, the order of
acquisition of the respective mechanisms and their contributions to the
resistance phenotype. We investigated two clinical isolates of E. coli, with different levels of resistance to ciprofloxacin (CIP)
but identical pulsed-field gel electrophoresis (PFGE) patterns, from
one patient. By gene exchange and complementation we demonstrated the
role of a C-terminal deletion in MarR resulting in increased efflux of
FQ in the more resistant strain.
(This study was presented in part at the 39th Interscience Conference
on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., 26 to
29 September, 1999.)
 |
MATERIALS AND METHODS |
Bacterial strains.
E. coli isolates EP1 and EP2 were
isolated from the vagina and the urine of a patient with generalized
follicular lymphoma who had received 750 mg of CIP twice daily for
selective decontamination of the gut. E. coli ATCC 25922 was
obtained from the American Type Culture Collection (ATCC). E. coli EP2 acrA::Tn10-Km was obtained from the clinical isolate EP2 by transposon mutagenesis and
screening for susceptibility against FQ. E. coli S17
pir harboring the plasmid pLOF/Km was kindly donated by V. de Lorenzo (6). E. coli S17 containing plasmid pBP591 with
wild-type marR has been described previously (V. Hüllen, P. Heisig, and B. Wiedemann, Abstr. 37th Intersci. Conf.
Antimicrob. Agents Chemother., abstr. C-64, p. 57, 1997).
PFGE.
A rapid PFGE procedure was performed as described
previously (8). Macrorestriction was performed with
XbaI at 37°C for 3 h. Electrophoresis was performed
with the contour-clamped homogeneous electric field (CHEF) mapper
system (Bio-Rad, Hercules, Calif.). The run time was 14 h, with an
initial switch time of 2.16 s and a final switch time of 35 s.
Susceptibility testing.
MICs of CIP were determined
according to NCCLS recommendations for microdilution assays
(16). MICs of chloramphenicol and tetracycline were
determined by Etest (AB BIODISK, Solna, Sweden). For testing of organic
solvent tolerance (OST), isolates were inoculated on Mueller-Hinton
agar at a concentration of 105 CFU per spot and the plate
was overlaid with hexane (H), cyclohexane (CH), and H-CH mixtures at
ratios of 3:1, 1:1, and 1:3 to generate different levels of organic
solvent toxicity. n-Hexane has a pow of 3.9, and cyclohexane has a pow of 3.4 (3). The plates were checked for growth after 2 days.
DNA amplification and nucleotide sequence determination.
Primers (Table 1) and PCR conditions for
amplification of gyrA, gyrB, and parE
were used as previously described (7, 12). Primers and
annealing temperatures for the amplification of parC, the
mar operon, marA and marB, and
acrA are listed in Table 1. Complementary strands were
sequenced in duplicate on a 310 DNA sequencer (Perkin-Elmer, Foster
City, Calif.) using either PCR primer (6 µmol).
Plasmids and DNA manipulations.
Strains and plasmids used in
this study are listed in Table 2.
Introduction of the marR frameshift mutation from isolate EP2 into the wild-type marR of isolate EP1 required
subcloning of the EcoRI/PstI-digested PCR
fragment (with primers marR-f1452 and
marR-r2229) into the corresponding pUC18 site to yield
plasmid pmarR-
C18. Probes for Northern blot analysis were generated
by subcloning of marA and soxS into plasmid
pcDNA3 (Invitrogen, Groningen, The Netherlands) and in vitro
transcription from the SP6 and T7 promoters, respectively. The complete
marA gene (1893 to 2282) was amplified in a DNA thermocycler
using primers marA-f1893 and marA-r2281. For
the amplification and cloning of soxS, primers soxS-f331 and soxS-r1319
were used. Genomic DNA from E. coli ATCC 25922 served as a
template. The PCR fragments were cloned directionally into plasmid
pcDNA3 to generate plasmids pc-marA and pc-soxS, respectively.
Recombinant DNA techniques, transformation, and restriction enzyme
digestions followed standard protocols (19).
Gene replacement.
Introduction of the marR
mutation into the wild-type marR gene of isolate EP1 was
accomplished by homologous recombination between plasmid pmarR-
C18
and the bacterial chromosome, essentially as described previously
(11). Plasmid pmarR-
C18 was introduced into isolate EP1
by electroporation (Genepulser; Bio-Rad). Resulting transformants were
grown on Luria-Bertani (LB) agar plates supplemented with 50 mg of
ampicillin/liter overnight at 37°C. Recombinant bacteria were then
propagated in LB broth containing 32 mg of CIP/liter for selection of
E. coli carrying the desired recombination. Segregation of
the plasmid after passaging of single colonies for 1 week was shown by
growth inhibition of recombinant clones on LB agar plates containing
ampicillin and by inability to amplify the specific marR DNA
fragment by PCR with plasmid DNA preparations as templates using
plasmid-specific primers.
Insertion mutagenesis.
Transposon mutagenesis was performed
using a suicide vector system as described previously (6,
10). The exconjugates were selected for reduced CIP MICs by
transfer of single colonies to agar plates containing 64 or 2 µg of
CIP/ml. Colonies growing selectively on plates with 2 µg of CIP/ml
were further analyzed.
RNA extraction and Northern blot analysis.
Overnight
cultures were diluted 100-fold in LB broth and grown with shaking to
mid-logarithmic phase at 37°C. Paraquat was added for the induction
of the sox operon (45 min; final concentration, 1.3 mM;
Sigma, Deisenhofen, Germany). For production of the marA probe, plasmid pc-marA was linearized by HindIII
digestion and in vitro RNA runoff transcription was performed with the
RiboProbe Kit (Promega). Similarly, the soxS probe was
obtained by XhoI digestion of plasmid pc-soxS and in vitro
transcription. Digoxigenin (DIG)-labeled RNA probes were purified with
the RNeasy Purification Kit (QIAGEN). The acrA probe was
obtained by PCR. Northern blotting was performed using standard
techniques (19).
Complementation assays.
For the complementation of the
mutant marR of isolate EP2, wild-type marR under
the control of the bla promoter was introduced into isolate
EP2 by mobilization with the filter mating technique. The donor strain,
E. coli S17 carrying plasmid pBP591, and isolate EP2 were
mixed in a 1:1 ratio and incubated at 37°C for 12 h on a minimal
agar plate. Cells were resuspended in LB broth and plated on LB agar
plates containing 50 µg of kanamycin/ml for selection.
Data analysis.
SPSS 8.0 for Windows was used for calculation
of Mann-Whitney U test results.
 |
RESULTS AND DISCUSSION |
PFGE typing generated identical patterns of
XbaI-digested total genomic DNA for isolates EP1 and EP2 but
different patterns for three epidemiologically unrelated strains used
as a control. Further evidence for the high genetic relatedness of the
two isolates was given by the finding of a 61-bp deletion and a 785-bp
insertion at the same site in both strains between bp 1252 and 1313 of
the published mar wild-type sequence (4) and by
observation of identical patterns in randomly primed PCR using five
different primers (data not shown).
The MICs of CIP for EP1 and EP2 were different, 16 and 256 mg/liter,
respectively; however, identical changes in critical residues of the
QRDRs of gyrA (Ser83Leu, Asp87Tyr) and parC
(Ser80Ile) were found. This combination of amino acid alterations in
critical residues can explain a CIP MIC of 16 mg/liter (12);
however, no other substitutions in the QRDR of gyrB or
parE were detected in any strain.
Compared to EP1, EP2 also required higher MICs of chloramphenicol (32 versus 4 mg/liter), tetracycline (32 versus 8 mg/liter), and cefuroxime
(>16 versus 4 mg/liter), and EP2 but not EP1 grew on Mueller-Hinton
agar overlaid with hexane or a 3:1 hexane-cyclohexane mixture. These
properties of EP2 were consistent with a Mar phenotype, and
consequently increased expression of the marA transcript was demonstrated by Northern blotting (Fig.
1A). Increased expression was
demonstrated independently by quantitative PCR using TaqMan technology
after a reverse PCR step (data not shown). Compared to wild-type
transcription of marA in strain ATCC 25922, transcription of
marA in isolate EP2 was estimated to be 64-fold, as
determined by twofold serial dilutions of the target sequence of
isolate EP2 (Fig. 1B). Expression of soxS, another
transcription factor of the acr locus (15), with
and without stimulation with paraquat, was similar in both isolates
(Northern blot, data not shown). The increased transcription of
marA in isolate EP2 led to increased expression of
acrA, as could be expected (1). In the
acrA Northern blot, two transcripts of approximately 4.5 and
2.2 kb were observed (Fig. 2). The size
of the larger transcript corresponds to the expected length of the
acrAB transcript of 4.344 kb, and this transcript is also
dominant. Sequencing of the mar operons of isolates EP1 and
EP2 indicated a deletion of adenine 1821 of marR in EP2.
This deletion resulted in a frameshift and a concomitant loss of 18 amino acids in the C-terminal region of the MarR protein.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 1.
Northern blot analyses of marA. (A) Total RNA
of E. coli was prepared, transferred to
Hybond-N+ membranes, and probed with DIG-labeled
marR RNA. The prominent transcripts and Boehringer RNA
molecular weight standard III are indicated. (B) A twofold serial
dilution of total RNA of E. coli isolate EP2 and undiluted
RNAs from E. coli isolate EP1 and strain ATCC 25922 were
transferred to Hybond-N+ membranes, stained with methylene
blue, and probed with DIG-labeled marR RNA.
|
|

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 2.
Northern blot analysis of acrAB. Total RNA
was prepared, transferred to Hybond-N+ membranes and probed
with DIG-labeled acrA PCR product. The prominent transcript
and Boehringer RNA molecular weight standard II are indicated.
|
|
To investigate the possible role of the truncation of MarR, gene
exchange and complementation experiments were designed. When we
introduced the defective marR into the chromosomal DNA of
isolate EP1 by homologous recombination, the MIC of CIP rose to 64 to 128 mg/liter, suggesting diminished repressor activity of the truncated
MarR. Likewise, in isolate EP2, in trans complementation with the wild-type marR resulted in a lower CIP MIC of 64 mg/liter. The putative role of the frameshift in marR
affecting the regulation of transcription of the AcrAB efflux pump was
corroborated by the knockout mutant EP2
acrA::Tn10-Km, for which the MIC of CIP fell back to 32 mg/liter. The characteristics of EP1, EP2, and their
derivatives are summarized in Table 3.
View this table:
[in this window]
[in a new window]
|
TABLE 3.
Characteristics of E. coli ATCC 25922, EP1,
EP2, EP2 acrA::Tn10-Km, EP1
marR, and EP2 complemented with
wild-type marR
|
|
Neither the introduction of the wild-type marR into isolate
EP2 nor the introduction of the defective marR into isolate
EP1 resulted in a complete reversal of CIP MICs, indicating an
additional, yet unknown resistance mechanism(s). The presence of
additional resistance mechanisms is also suggested by the author of a
recent study of E. coli with GyrA and MarA mutations
generated in vitro, in which no clinically relevant resistance to CIP
was detectable in acrAB knockout mutants (17).
Efflux pump inhibitors, which restored susceptibility to FQ in the
presence of target mutations (13), may not be effective in
the E. coli clinical isolate EP2 analyzed in this study.
The multiple antibiotic resistance locus (mar) of E. coli controls intrinsic susceptibility to multiple antibiotics,
organic solvents, oxidative stress agents, and the disinfectant
triclosan (for reviews see references 1, 2, and
14). Presumably, the N-terminal and central regions
of MarR, where a helix-turn-helix motif has been identified, are
responsible for the specific interactions with the two binding sites in
marO (1). The finding of this study indicates
that the C terminus of MarR is also necessary for proper repressor function.
In conclusion, using genetic exchange and complementation techniques in
an otherwise genetically indistinguishable pair of clinical isolates of
E. coli, we have identified a unique C-terminal deletion
in MarR resulting in a Mar phenotype affecting the MICs of FQ,
tetracycline, chloramphenicol, and cefuroxime, as well as OST. Changes
in the target enzyme and active efflux both add to the resistance
phenotype. This is yet another example of the versatility of bacterial
acquisition of antimicrobial resistance.
 |
ACKNOWLEDGMENTS |
We gratefully acknowledge the technical assistance of Emmi Fuchs
and Christine Irtenkauf. Nucleotide sequence determination was
performed by Holger Melzl and Josef Köstler.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Institut
für Medizinische Mikrobiologie und Hygiene,
Universität Regensburg, Franz-Josef-Strauss-Allee 11, D-93049
Regensburg, Germany. Phone: 49-941-944-6411. Fax: 49-941-944-6439. E-mail:
norbert.lehn{at}klinik.uni-regensburg.de.
 |
REFERENCES |
| 1.
|
Alekshun, M. N., and S. B. Levy.
1997.
Regulation of chromosomally mediated multiple antibiotic resistance: the mar regulon.
Antimicrob. Agents Chemother.
41:2067-2075[Medline].
|
| 2.
|
Alekshun, M. N., and S. B. Levy.
1999.
The mar regulon: multiple resistance to antibiotics and other toxic chemicals.
Trends Microbiol.
7:410-413[CrossRef][Medline].
|
| 3.
|
Aono, R.
1998.
Improvement of organic solvent tolerance level of Escherichia coli by overexpression of stress-responsive genes.
Extremophiles
2:239-248[CrossRef][Medline].
|
| 4.
|
Cohen, S. P.,
H. Hachler, and S. B. Levy.
1993.
Genetic and functional analysis of the multiple antibiotic resistance (mar) locus in Escherichia coli.
J. Bacteriol.
175:1484-1492[Abstract/Free Full Text].
|
| 5.
|
Cohen, S. P.,
L. M. McMurry,
D. C. Hooper,
J. S. Wolfson, and S. B. Levy.
1989.
Cross-resistance to fluoroquinolones in multiple-antibiotic-resistant (Mar) Escherichia coli selected by tetracycline or chloramphenicol: decreased drug accumulation associated with membrane changes in addition to OmpF reduction.
Antimicrob. Agents Chemother.
33:1318-1325[Abstract/Free Full Text].
|
| 6.
|
de Lorenzo, V., and K. N. Timmis.
1994.
Analysis and construction of stable phenotypes in gram-negative bacteria with Tn5- and Tn10-derived minitransposons.
Methods Enzymol.
235:386-405[Medline].
|
| 7.
|
Everett, M. J.,
Y. F. Jin,
V. Ricci, and L. J. Piddock.
1996.
Contributions of individual mechanisms to fluoroquinolone resistance in 36 Escherichia coli strains isolated from humans and animals.
Antimicrob. Agents Chemother.
40:2380-2386[Abstract].
|
| 8.
|
Gautom, R. K.
1997.
Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day.
J. Clin. Microbiol.
35:2977-2980[Abstract].
|
| 9.
|
Heisig, P.
1996.
Genetic evidence for a role of parC mutations in development of high-level fluoroquinolone resistance in Escherichia coli.
Antimicrob. Agents Chemother.
40:879-885[Abstract].
|
| 10.
|
Herrero, M.,
V. de Lorenzo, and K. N. Timmis.
1990.
Transposon vectors containing non-antibiotic resistance selection markers for cloning and stable chromosomal insertion of foreign genes in gram-negative bacteria.
J. Bacteriol.
172:6557-6567[Abstract/Free Full Text].
|
| 11.
|
Kiel, J. A.,
J. P. Vossen, and G. Venema.
1987.
A general method for the construction of Escherichia coli mutants by homologous recombination and plasmid segregation.
Mol. Gen. Genet.
207:294-301[CrossRef][Medline].
|
| 12.
|
Lehn, N.,
J. Stoewer-Hoffmann,
T. Kott,
C. Strassner,
H. Wagner, and W. Schneider-Brachert.
1996.
Characterization of clinical isolates of Escherichia coli showing high levels of fluoroquinolone resistance.
J. Clin. Microbiol.
34:597-602[Abstract].
|
| 13.
|
Lomovskaya, O.,
A. Lee,
K. Hoshino,
H. Ishida,
A. Mistry,
M. S. Warren,
E. Boyer,
S. Chamberland, and V. J. Lee.
1999.
Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa.
Antimicrob. Agents Chemother.
43:1340-1346[Abstract/Free Full Text].
|
| 14.
|
McMurry, L. M.,
M. Oethinger, and S. B. Levy.
1998.
Overexpression of marA, soxS, or acrAB produces resistance to triclosan in laboratory and clinical strains of Escherichia coli.
FEMS Microbiol. Lett.
166:305-309[CrossRef][Medline].
|
| 15.
|
Miller, P. F., and M. C. Sulavik.
1996.
Overlaps and parallels in the regulation of intrinsic multiple-antibiotic resistance in Escherichia coli.
Mol. Microbiol.
21:441-448[CrossRef][Medline].
|
| 16.
|
National Committee for Clinical Laboratory Standards.
1997.
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed.
Approved standard. NCCLS document M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
|
| 17.
|
Oethinger, M.,
W. V. Kern,
A. S. Jellen-Ritter,
L. M. McMurry, and S. B. Levy.
2000.
Ineffectiveness of topoisomerase mutations in mediating clinically significant fluoroquinolone resistance in Escherichia coli in the absence of the AcrAB efflux pump.
Antimicrob. Agents Chemother.
44:10-13[Abstract/Free Full Text].
|
| 18.
|
Oethinger, M.,
I. Podglajen,
W. V. Kern, and S. B. Levy.
1998.
Overexpression of the marA or soxS regulatory gene in clinical topoisomerase mutants of Escherichia coli.
Antimicrob. Agents Chemother.
42:2089-2094[Abstract/Free Full Text].
|
| 19.
|
Sambrook, J.,
E. F. Fritsch, and T. Maniatis.
1989.
Molecular cloning: a laboratory manual, 2nd ed.
Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
|
Antimicrobial Agents and Chemotherapy, July 2000, p. 1865-1868, Vol. 44, No. 7
0066-4804/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Perez, A., Canle, D., Latasa, C., Poza, M., Beceiro, A., del Mar Tomas, M., Fernandez, A., Mallo, S., Perez, S., Molina, F., Villanueva, R., Lasa, I., Bou, G.
(2007). Cloning, Nucleotide Sequencing, and Analysis of the AcrAB-TolC Efflux Pump of Enterobacter cloacae and Determination of Its Involvement in Antibiotic Resistance in a Clinical Isolate. Antimicrob. Agents Chemother.
51: 3247-3253
[Abstract]
[Full Text]
-
Casaz, P., Garrity-Ryan, L. K., McKenney, D., Jackson, C., Levy, S. B., Tanaka, S. K., Alekshun, M. N.
(2006). MarA, SoxS and Rob function as virulence factors in an Escherichia coli murine model of ascending pyelonephritis. Microbiology
152: 3643-3650
[Abstract]
[Full Text]
-
Ling, J. M., Chan, E. W., Lam, A. W., Cheng, A. F.
(2003). Mutations in Topoisomerase Genes of Fluoroquinolone-Resistant Salmonellae in Hong Kong. Antimicrob. Agents Chemother.
47: 3567-3573
[Abstract]
[Full Text]
-
Komp Lindgren, P., Karlsson, A., Hughes, D.
(2003). Mutation Rate and Evolution of Fluoroquinolone Resistance in Escherichia coli Isolates from Patients with Urinary Tract Infections. Antimicrob. Agents Chemother.
47: 3222-3232
[Abstract]
[Full Text]
-
Bina, X., Perreten, V., Levy, S. B.
(2003). The Periplasmic Protein MppA Requires an Additional Mutated Locus To Repress marA Expression in Escherichia coli. J. Bacteriol.
185: 1465-1469
[Abstract]
[Full Text]
-
Linde, H.-J., Notka, F., Irtenkauf, C., Decker, J., Wild, J., Niller, H.-H., Heisig, P., Lehn, N.
(2002). Increase in MICs of ciprofloxacin in vivo in two closely related clinical isolates of Enterobacter cloacae. J Antimicrob Chemother
49: 625-630
[Abstract]
[Full Text]
-
Chollet, R., Bollet, C., Chevalier, J., Mallea, M., Pages, J.-M., Davin-Regli, A.
(2002). mar Operon Involved in Multidrug Resistance of Enterobacter aerogenes. Antimicrob. Agents Chemother.
46: 1093-1097
[Abstract]
[Full Text]
-
Notka, F., Linde, H.-J., Dankesreiter, A., Niller, H.-H., Lehn, N.
(2002). A C-terminal 18 amino acid deletion in MarR in a clinical isolate of Escherichia coli reduces MarR binding properties and increases the MIC of ciprofloxacin. J Antimicrob Chemother
49: 41-47
[Abstract]
[Full Text]